Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nureca Limited (NURECA.NS)
Chandigarh, IN
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditions like nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers. They also provide orthopedic aids such as massagers, pain monitoring devices, posture correctors, and rehabilitation equipment. Further offerings include humidifiers and steamers, personal weighing scales, yoga and exercise accessories, fitness trackers, and dental and personal hygiene essentials. Additionally, Nureca caters to mother and infant care with products like baby feeding accessories, carry cots, baby skincare items, and bottle warmers/sterilizers. They also supply nutritional supplements, weight management aids, and advanced monitoring devices such as ECG machines, activity trackers, and smart scales. These diverse offerings are marketed under their proprietary brands: Dr Trust, Dr Physio, and Trumom. Distribution occurs through a multi-channel approach, utilizing third-party e-commerce platforms, a network of distributors and retailers, as well as their direct-to-consumer website, drtrust.in. Established in 2016, Nureca Limited is headquartered in Chandigarh, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.69% | -0.90% | -16.16% | -9.85% | -21.97% | -24.63% | -17.00% | -38.70% | -85.39% | -64.06% | -64.06% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Devices: +11.2%+34.0% ★ Q1'26: +11.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+148.2% ★ Q1'26: -361.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-3.3% Q1'26: -2.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+4.4% Q1'26: +6.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+2.8% Q1'26: +6.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-1.6% ★ Q1'26: -5.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.27× ★ Q1'26: 0.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-10 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-09 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-05 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-04 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-03 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-02 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aryan Goyal | Co-Founder, Chief Executive Officer & Whole-time Director | 20M | male |
| Saurabh Goyal | Co-Founder, MD & Chairman | 19M | male |
| Nishu Kansal | Company Secretary & Compliance Officer | 1M | female |
| Rajinder Sharma | Whole-Time Director | 300.0K | male |
| Gurvikram Singh | Assistant Mang. of Investors Relations & Corporation Affairs | 260.0K | male |
| Rohit Saini | Vice President of Sales & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NURECA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
